Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
Frontiers in Immunology|August 6, 2026
Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosingAlex Agundez-Moreno, Silvia Presas-Rodríguez, Antonio Manuel González-García, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Multiple Sclerosis and Related Disorders|December 20, 2025
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-studyHelmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Journal of Neurology|April 14, 2025
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort studyPakeeran Siriratnam, Saif Huda, Anneke Van der Walt, et al.
International Journal of Molecular Sciences|June 12, 2026
Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple SclerosisLucienne Costa-Frossard, Luis Brieva, Daniel Apolinar García-Estévez, et al.
Frontiers in Neurology|May 14, 2025
An expert patient program for people living with multiple sclerosis improves knowledge and empowerment: a pre-test, post-test multicenter implementation studyMiguel Ángel Robles-Sánchez, Paloma Amil-Bujan, Cristina Bosch-Farré, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 5, 2016
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatusMaria Sepúlveda, Thaís Armangué, Nuria Sola-Valls, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2017
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimatesMaria Sepúlveda, Marta Aldea, Domingo Escudero, et al.
Pageof 9